Holy Stone Healthcare Co., Ltd.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.hshc.com.tw
Clinical Trials
6
Active:1
Completed:3
Trial Phases
2 Phases
Phase 1:3
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Phase 2
2 (40.0%)Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Holy Stone Healthcare Co., Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT06039202
Individual Patient Expanded Access to CA102N
- Conditions
- Advanced or Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Holy Stone Healthcare Co., Ltd
- Registration Number
- NCT05274204
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced or Metastatic Colorectal Cancer (mCRC)Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Holy Stone Healthcare Co., Ltd
- Target Recruit Count
- 37
- Registration Number
- NCT03616574
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M
Phase 2
Completed
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: PlaceboDrug: Low doseDrug: High dose
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Holy Stone Healthcare Co., Ltd
- Target Recruit Count
- 51
- Registration Number
- NCT02493712
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Milan, Italy
Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Holy Stone Healthcare Co., Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT02196662
- Locations
- 🇨🇦
inVentiv Health Clinique, Quebec, Canada
News
No news found